When was Eleusis founded?

Eleusis was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Eleusis located?

Eleusis is headquartered in London, United Kingdom.

Which legal entities is Eleusis associated with?

Eleusis is associated with ELEUSIS HOLDINGS LIMITED.

How many employees does Eleusis have?

As of Sep 30, 2026, the latest employee count at Eleusis is 31.

Is Eleusis a funded company?

Eleusis is a funded company, having raised a total of $1.47M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 07, 2014.

When was the latest funding round of Eleusis?

Eleusis' latest funding was a $***** Seed round on Mar 04, 2022, with participation from 0 investor.

Where does Eleusis rank among its competitors?

Eleusis ranks 59th amongst 346 active competitors, of which 124 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Trimtech Therapeutics, which secured $14M in Jun, 2026.

Who are the top competitors of Eleusis?

Eleusis' top competitors include Upstream Bio, Odyssey and Septerna. Among them, Trimtech Therapeutics secured the most recent funding round in June, 2026.

Eleusis - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of immunomodulatory and neuroprotective medicines. The company has developed a portfolio of drug candidates to address unmet needs within and beyond psychiatry. The lead program of the company is ELE-Psilo for the treatment of depression.

Website: eleusisltd.com
Email ID: *****@eleusisltd.com

Key Metrics

Founded Year

2013

Location

London, United Kingdom

Stage

Acquired

Total Funding

$1.47M in 3 rounds

Latest Funding Round

Seed, Mar 04, 2022, $*****

Investors

Palo Santo & 5 more

Ranked

59^th among 346 active competitors

Employee Count

31 as on Sep 30, 2026

Investment & Acquisitions

Kalypso

Similar Companies

Upstream Bio & 416 more

Exit Details

Acquired by Beckley Psytech (Oct 24, 2022)

View Eleusis' full profile

Eleusis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ELEUSIS HOLDINGS LIMITED CIN: 10809365 , United Kingdom, Active	Jun 07, 2017	-	2 (As on Dec 31, 2024)

Eleusis got acquired by Beckley Psytech on Oct 24, 2022.

Click here to take a look at Eleusis's acquisition in detail

Eleusis has raised a total funding of $1.47M over 3 rounds. Its first funding round was on Feb 07, 2014. Eleusis has 6 institutional investors.

Here is the list of recent funding rounds of Eleusis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2022	1619948	Seed	5781557	9247074	9640215	8073158
May 20, 2016	4050170	Seed	1572539	2143673	2220351	3294922
Feb 07, 2014	1130062	Seed	4113229	5617327	5732050	6320203

Access funding benchmarks and valuations. Sign up today!

View details of Eleusis's funding rounds and investors

The founders of Eleusis are Shlomi Raz and Charles D. Nichols.

Here are the details of Eleusis' key team members:

Shlomi Raz: Co-Founder & CEO of Eleusis.
Charles D. Nichols: Co-Founder of Eleusis.

View details of Eleusis's Founder profiles and Board Members

Eleusis' employee count trend

Eleusis has 31 employees as of Sep 26. Here is Eleusis's employee count trend over the years:

Uncover Eleusis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eleusis include Upstream Bio, Odyssey and Septerna. Here is the list of Top 10 competitors of Eleusis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	66/100
2nd	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
3rd	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
4th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
5th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
6th	COMPASS Pathways 2016, London (United Kingdom), Public	Developer of therapies for treating mental disorders	$109M	Perceptive Advisors, Able Partners & 20 others	66/100
7th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, Valence Life Sciences & 11 others	64/100
8th	Vyome Therapeutics 2010, Princeton (United States), Public	Developer of therapeutics for the immuno-inflammatory conditions	$62.9M	Perceptive Advisors, Iron Pillar & 11 others	64/100
9th	Apollo Therapeutics 2020, Cambridge (United Kingdom), Series C	Developer of therapeutic programs based on biological and medical research	$372M	Patient Square Capital, Rock Springs Capital ... & 3 others	61/100
10th	Trimtech Therapeutics 2023, Cambridge (United Kingdom), Seed	They develop treatments for CNS and inflammatory disorders	$47M	Cambridge Innovation Capital, SV Health Investors ... & 11 others	61/100
59th	Eleusis 2013, London (United Kingdom), Acquired	Developer of immunomodulatory and neuroprotective medicines	$1.47M	Palo Santo, Noetic Psychedelic Fund & 4 others	47/100